Text Size
3 studies found for:    trabedersen

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Completed Safety and Tolerability of AP 12009, Administered I.V. in Patients With Advanced Tumors Known to Overproduce TGF-beta-2
Conditions: Pancreatic Neoplasms;   Melanoma;   Colorectal Neoplasms
Intervention: Drug: AP 12009
2 Completed Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma
Conditions: Glioblastoma;   Anaplastic Astrocytoma
Interventions: Drug: AP 12009 10 µM;   Drug: AP 12009 80 µM;   Drug: temozolomide or PCV;   Device: Drug delivery system for administration of AP 12009;   Procedure: Placement of Drug Delivery System
3 Terminated Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma
Conditions: Anaplastic Astrocytoma;   Glioblastoma
Interventions: Drug: trabedersen;   Drug: temozolomide;   Device: Drug delivery system for administration of AP 12009;   Procedure: Placement of Drug Delivery System;   Drug: carmustine;   Drug: lomustine
To Top

† Indicates status has not been verified in more than two years